GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » Debt-to-EBITDA

Precigen (Precigen) Debt-to-EBITDA : -0.06 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Precigen Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Precigen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.20 Mil. Precigen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.90 Mil. Precigen's annualized EBITDA for the quarter that ended in Dec. 2023 was $-127.07 Mil. Precigen's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Precigen's Debt-to-EBITDA or its related term are showing as below:

PGEN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.38   Med: -0.39   Max: -0.05
Current: -0.08

During the past 13 years, the highest Debt-to-EBITDA Ratio of Precigen was -0.05. The lowest was -3.38. And the median was -0.39.

PGEN's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs PGEN: -0.08

Precigen Debt-to-EBITDA Historical Data

The historical data trend for Precigen's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Debt-to-EBITDA Chart

Precigen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.38 -2.68 -2.42 -0.82 -0.08

Precigen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.65 -0.26 -0.11 -0.10 -0.06

Competitive Comparison of Precigen's Debt-to-EBITDA

For the Biotechnology subindustry, Precigen's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precigen's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precigen's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Precigen's Debt-to-EBITDA falls into.



Precigen Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Precigen's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.202 + 5.895) / -89.226
=-0.08

Precigen's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.202 + 5.895) / -127.068
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Precigen  (NAS:PGEN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Precigen Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Precigen's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Precigen (Precigen) Business Description

Traded in Other Exchanges
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Executives
Jeffrey B Kindler director 35 E. 62ND ST, NEW YORK NY 10065
Randal J Kirk director, 10 percent owner, officer: Chief Executive Officer 1881 GROVE AVENUE, RADFORD VA 24141
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari director, officer: President and CEO 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah officer: Chief Operating Officer C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian officer: Chief Financial Officer C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Jeffrey Thomas Perez officer: SVP, IP Affairs 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Donald P. Lehr officer: Chief Legal Officer 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro director 155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez director C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley director 9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a. 10 percent owner ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170

Precigen (Precigen) Headlines

From GuruFocus